Get started
TELIX PHARMACEUTICALS LIMITEDTELIX PHARMACEUTICALS LIMITEDTELIX PHARMACEUTICALS LIMITED

TELIX PHARMACEUTICALS LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TLX chart


Full chart

TLX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.37 B‬ AUD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
166.58
Basic EPS (TTM)
0.15 AUD
Net income (FY)
‪5.21 M‬ AUD
Revenue (FY)
‪502.55 M‬ AUD
Shares float
‪254.25 M‬
Beta (1Y)
1.28

About TELIX PHARMACEUTICALS LIMITED


Sector
Health Technology
Industry
Biotechnology
CEO
Christian P. Behrenbruch
Website
telixpharma.com
Headquarters
Melbourne
Founded
2017
ISIN
AU000000TLX2
FIGI
BBG00HZHXWN4
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TLX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TLX is 25.02 AUD — it has increased by 1.62% in the past 24 hours. Watch TELIX PHARMACEUTICALS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange TELIX PHARMACEUTICALS LIMITED stocks are traded under the ticker TLX.
TLX stock has risen by 0.08% compared to the previous week, the month change is a 11.00% rise, over the last year TELIX PHARMACEUTICALS LIMITED has showed a 157.67% increase.
We've gathered analysts' opinions on TELIX PHARMACEUTICALS LIMITED future price: according to them, TLX price has a max estimate of 33.40 AUD and a min estimate of 21.60 AUD. Watch TLX chart and read a more detailed TELIX PHARMACEUTICALS LIMITED stock forecast: see what analysts think of TELIX PHARMACEUTICALS LIMITED and suggest that you do with its stocks.
TLX reached its all-time high on Dec 18, 2024 with the price of 25.80 AUD, and its all-time low was 0.46 AUD and was reached on Feb 20, 2018. View more price dynamics on TLX chart.
See other stocks reaching their highest and lowest prices.
TLX stock is 2.12% volatile and has beta coefficient of 1.28. Track TELIX PHARMACEUTICALS LIMITED stock price on the chart and check out the list of the most volatile stocks — is TELIX PHARMACEUTICALS LIMITED there?
Today TELIX PHARMACEUTICALS LIMITED has the market capitalization of ‪8.37 B‬, it has decreased by −1.28% over the last week.
Yes, you can track TELIX PHARMACEUTICALS LIMITED financials in yearly and quarterly reports right on TradingView.
TELIX PHARMACEUTICALS LIMITED is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
TELIX PHARMACEUTICALS LIMITED revenue for the last quarter amounts to ‪175.00 M‬ AUD, despite the estimated figure of ‪175.00 M‬ AUD. In the next quarter, revenue is expected to reach ‪403.22 M‬ AUD.
TLX net income for the last half-year is ‪29.65 M‬ AUD, while the previous report showed ‪19.53 M‬ AUD of net income which accounts for 51.83% change. Track more TELIX PHARMACEUTICALS LIMITED financial stats to get the full picture.
No, TLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TELIX PHARMACEUTICALS LIMITED EBITDA is ‪72.17 M‬ AUD, and current EBITDA margin is 11.63%. See more stats in TELIX PHARMACEUTICALS LIMITED financial statements.
Like other stocks, TLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TELIX PHARMACEUTICALS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TELIX PHARMACEUTICALS LIMITED technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TELIX PHARMACEUTICALS LIMITED stock shows the buy signal. See more of TELIX PHARMACEUTICALS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.